NCT03267225View on ClinicalTrials.gov

Genetic Determinants of Clindamycin/Rifampin Interaction

CompletedOBSERVATIONAL
Enrollment

84

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 15, 2021

Study Completion Date

April 15, 2021

Conditions
VA Drug Interaction
Trial Locations (1)

75020

Groupe Hospitalier Diaconesses Croix Saint Simon, Paris

All Listed Sponsors
collaborator

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

lead

Dr Valerie ZELLER

OTHER

NCT03267225 - Genetic Determinants of Clindamycin/Rifampin Interaction | Biotech Hunter | Biotech Hunter